Literature DB >> 1017718

Intravenous administration of diazepam in patients with chronic liver disease.

R A Branch, M H Morgan, J James, A E Read.   

Abstract

The EEG response and drug kinetics after intravenous infusion of diazepam at 1-0 mg/min until nystagmus, dysarthria, and moderate sedation developed, has been investigated in five normal subjects and 17 patients with chronic liver disease. Diazepam induced adequate premedication with a similar clinical response in all subjects with no adverse reactions. Maximal response was during or within five minutes of infusion. The dose of diazepam required in liver chronic disease was 17-9 +/- 1-4 mg (M +/- SEM) compared with 27 +/- 5-4 mg in controls (p less than 0-01). Dose correlated significantly with serum albumin (p less than 0-05). Baseline mean dominant frequency (MDF) and slow wave index (SWI) significantly correlated with albumin (p less than 0-01). After diazepam, the MDF decreased and SWI increased. The change was greatest at the time of maximal clinical response. It was greater in liverdisease and was greatest in patients with previous hepaticencephalopathy. In spite of reduced dose requirements in liver disease, there was no significant difference in plasma concentration at the end of drug infusion...

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1017718      PMCID: PMC1411230          DOI: 10.1136/gut.17.12.975

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  23 in total

1.  The use of indocyanine green in the measurement of hepatic blood flow and as a test of hepatic function.

Authors:  J CAESAR; S SHALDON; L CHIANDUSSI; L GUEVARA; S SHERLOCK
Journal:  Clin Sci       Date:  1961-08       Impact factor: 6.124

2.  Hepatic coma: the electroencephalographic pattern.

Authors:  R G BICKFORD; H R BUTT
Journal:  J Clin Invest       Date:  1955-06       Impact factor: 14.808

3.  The E.E.G. in hepatic encephalopathy.

Authors:  J LAIDLAW; A E READ
Journal:  Clin Sci       Date:  1963-02       Impact factor: 6.124

4.  The electroencephalographic diagnosis of manifest and latent 'delirium' with particular reference to that complicating hepatic cirrhosis.

Authors:  J LAIDLAW; A E READ
Journal:  J Neurol Neurosurg Psychiatry       Date:  1961-02       Impact factor: 10.154

5.  Neuropsychiatric complications following chlorothiazide therapy in patients with hepatic cirrhosis: possible relation to hypokalaemia.

Authors:  A E READ; J LAIDLAW; R M HASLAM; S SHERLOCK
Journal:  Clin Sci       Date:  1959-08       Impact factor: 6.124

6.  Portal-systemic encephalopathy; neurological complications of liver disease.

Authors:  S SHERLOCK; W H SUMMERSKILL; L P WHITE; E A PHEAR
Journal:  Lancet       Date:  1954-09-04       Impact factor: 79.321

7.  A study of factors influencing drug disposition in chronic liver disease, using the model drug (+)-propranolol.

Authors:  R A Branch; J James; A E Read
Journal:  Br J Clin Pharmacol       Date:  1976-04       Impact factor: 4.335

Review 8.  Propranolol disposition in chronic liver disease: a physiological approach.

Authors:  R A Branch; D G Shand
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

9.  Determinants of serum antipyrine half-lives in patients with liver disease.

Authors:  R A Branch; C M Herbert; A E Read
Journal:  Gut       Date:  1973-07       Impact factor: 23.059

10.  Metabolism of amylobarbitone in patients with chronic liver disease.

Authors:  G E Mawer; N E Miller; L A Turnberg
Journal:  Br J Pharmacol       Date:  1972-03       Impact factor: 8.739

View more
  24 in total

Review 1.  Sedation for fibreoptic bronchoscopy.

Authors:  M P Shelley; P Wilson; J Norman
Journal:  Thorax       Date:  1989-10       Impact factor: 9.139

Review 2.  Clinical pharmacokinetics in patients with liver disease.

Authors:  A J McLean; D J Morgan
Journal:  Clin Pharmacokinet       Date:  1991-07       Impact factor: 6.447

3.  Maintenance time of sedative effects after an intravenous infusion of diazepam: a guide for endoscopy using diazepam.

Authors:  Mitsushige Sugimoto; Takahisa Furuta; Akiko Nakamura; Naohito Shirai; Mutsuhiro Ikuma; Shingen Misaka; Shinya Uchida; Hiroshi Watanabe; Kyoichi Ohashi; Takashi Ishizaki; Akira Hishida
Journal:  World J Gastroenterol       Date:  2008-09-07       Impact factor: 5.742

4.  Sedation in liver disease.

Authors: 
Journal:  Br Med J       Date:  1977-05-14

Review 5.  Guide to drug dosage in hepatic disease.

Authors:  N M Bass; R L Williams
Journal:  Clin Pharmacokinet       Date:  1988-12       Impact factor: 6.447

6.  Effects of liver disease and of aging on the disposition and elimination of sedatives.

Authors:  S Schenker
Journal:  Trans Am Clin Climatol Assoc       Date:  1978

Review 7.  Some clinical features of liver cell failure: an appraisal of their causes.

Authors:  A E Read
Journal:  Gut       Date:  1978-06       Impact factor: 23.059

8.  Sources of Interindividual Variability.

Authors:  Yvonne S Lin; Kenneth E Thummel; Brice D Thompson; Rheem A Totah; Christi W Cho
Journal:  Methods Mol Biol       Date:  2021

Review 9.  Use of benzodiazepines during pregnancy, labour and lactation, with particular reference to pharmacokinetic considerations.

Authors:  J H Kanto
Journal:  Drugs       Date:  1982-05       Impact factor: 9.546

Review 10.  Drug prescribing in hepatobiliary disease.

Authors:  R K Roberts; P V Desmond; S Schenker
Journal:  Drugs       Date:  1979-03       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.